# Ophthalmology Sector

Canonical URL: https://biopharmsignal.com/sector/ophthalmology

Ophthalmology includes companies developing therapies, devices, and diagnostics for diseases of the eye, including retinal disorders, glaucoma, dry eye, and surgical vision care. This page groups businesses exposed to both therapeutic and procedure-driven eye care markets.

Companies currently grouped under Ophthalmology: 21

## Recent Sector News

- 2026-07-02 08:00 EST — OCS — [Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference](https://biopharmsignal.com/news/OCS/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference-17f42704) — Source: Oculis
- 2026-07-02 08:00 EST — OCS — [Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference](https://biopharmsignal.com/news/OCS/oculis-to-participate-at-the-piper-sandler-virtual-ophthalmology-conference-4eee9c99) — Source: Oculis
- 2026-06-25 13:46 EST — OCS — [Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026](https://biopharmsignal.com/news/OCS/oculis-to-present-privosegtor-at-upcoming-clinical-trials-at-the-summit-2026) — Source: Oculis
- 2026-06-25 13:46 EST — IRIX — [Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference](https://biopharmsignal.com/news/IRIX/iridex-to-present-at-the-planet-microcap-las-vegas-2026-conference) — Source: IRIDEX
- 2026-06-25 13:46 EST — OCS — [Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease](https://biopharmsignal.com/news/OCS/oculis-announces-first-patient-randomized-in-predict-1-registrational-trial-of-licaminlimab-advancing-precision-medicine-in-dry-eye-disease) — Source: Oculis
- 2026-06-25 13:46 EST — OCS — [Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference](https://biopharmsignal.com/news/OCS/oculis-to-present-at-the-47th-annual-goldman-sachs-global-healthcare-conference) — Source: Oculis
- 2026-06-25 13:46 EST — OCS — [Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema](https://biopharmsignal.com/news/OCS/oculis-announces-topline-results-from-diamond-phase-3-trials-with-ocs-01-in-diabetic-macular-edema) — Source: Oculis
- 2026-06-25 13:46 EST — IRIX — [Iridex Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/IRIX/iridex-reports-first-quarter-2026-financial-results) — Source: IRIDEX
- 2026-06-25 13:46 EST — OCS — [Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors](https://biopharmsignal.com/news/OCS/oculis-publishes-results-of-2026-annual-general-meeting-and-announces-election-of-gregory-d-perry-to-its-board-of-directors) — Source: Oculis
- 2026-06-25 13:46 EST — TARS — [Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans](https://biopharmsignal.com/news/TARS/tarsus-and-john-cena-partner-to-raise-awareness-of-demodex-blepharitis-a-common-eyelid-disease-affecting-approximately-25-million-americans) — Source: Tarsus Pharmaceuticals
- 2026-06-25 13:46 EST — OCS — [Oculis Reports Q1 2026 Financial Results and Provides Company Update](https://biopharmsignal.com/news/OCS/oculis-reports-q1-2026-financial-results-and-provides-company-update) — Source: Oculis
- 2026-06-25 13:46 EST — OCS — [Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial](https://biopharmsignal.com/news/OCS/oculis-announces-agreement-with-fda-on-a-special-protocol-assessment-spa-for-optic-neuritis-registrational-trial) — Source: Oculis
- 2026-06-25 13:46 EST — TARS — [Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements](https://biopharmsignal.com/news/TARS/tarsus-reports-first-quarter-2026-financial-results-and-recent-business-achievements) — Source: Tarsus Pharmaceuticals
- 2026-06-25 13:46 EST — SGHT — [Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance](https://biopharmsignal.com/news/SGHT/sight-sciences-reports-first-quarter-2026-financial-results-and-raises-full-year-2026-revenue-guidance) — Source: Sight Sciences
- 2026-06-25 13:46 EST — CARM — [Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024](https://biopharmsignal.com/news/CARM/carisma-therapeutics-to-present-new-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocellular-carcinoma-at-sitc-2024) — Source: Carisma Therapeutics, Inc.
- 2026-06-25 13:46 EST — CARM — [Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/CARM/carisma-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights) — Source: Carisma Therapeutics, Inc.
- 2026-06-25 13:46 EST — CARM — [Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma](https://biopharmsignal.com/news/CARM/carisma-unveils-promising-pre-clinical-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocellular-carcinoma) — Source: Carisma Therapeutics, Inc.
- 2026-06-25 13:46 EST — CARM — [Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024](https://biopharmsignal.com/news/CARM/carisma-therapeutics-presents-promising-new-preclinical-data-on-engineered-macrophages-for-the-treatment-of-liver-fibrosis-at-aasld-the-liver-meetingr-2024) — Source: Carisma Therapeutics, Inc.
- 2026-06-25 13:46 EST — CARM — [Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference](https://biopharmsignal.com/news/CARM/carisma-therapeutics-to-participate-in-the-7th-annual-evercore-isi-healthconx-conference) — Source: Carisma Therapeutics, Inc.
- 2026-06-25 13:46 EST — CARM — [Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline](https://biopharmsignal.com/news/CARM/carisma-therapeutics-announces-strategic-restructuring-to-re-prioritize-pipeline) — Source: Carisma Therapeutics, Inc.

## Companies

- [ADVM](https://biopharmsignal.com/company/ADVM) — Adverum Biotechnologies
- [ALC](https://biopharmsignal.com/company/ALC) — Alcon Inc.
- [ALIM](https://biopharmsignal.com/company/ALIM) — Alimera Sciences
- [AURA](https://biopharmsignal.com/company/AURA) — Aura Biosciences
- [CARM](https://biopharmsignal.com/company/CARM) — Carisma Therapeutics, Inc.
- [EYEN](https://biopharmsignal.com/company/EYEN) — Eyenovia
- [EYPT](https://biopharmsignal.com/company/EYPT) — EyePoint Pharmaceuticals
- [GKOS](https://biopharmsignal.com/company/GKOS) — Glaukos Corporation
- [GRAY](https://biopharmsignal.com/company/GRAY) — Graybug
- [GHSI](https://biopharmsignal.com/company/GHSI) — Guardion Health Sciences
- [HROW](https://biopharmsignal.com/company/HROW) — Harrow, Inc.
- [IRIX](https://biopharmsignal.com/company/IRIX) — IRIDEX
- [KALA](https://biopharmsignal.com/company/KALA) — KALA BIO
- [EYE](https://biopharmsignal.com/company/EYE) — National Vision
- [NBY](https://biopharmsignal.com/company/NBY) — Novabay Pharmaceuticals
- [OCGN](https://biopharmsignal.com/company/OCGN) — Ocugen
- [OCUL](https://biopharmsignal.com/company/OCUL) — Ocular Therapeutix
- [OCS](https://biopharmsignal.com/company/OCS) — Oculis
- [OKYO](https://biopharmsignal.com/company/OKYO) — OKYO Pharma
- [SGHT](https://biopharmsignal.com/company/SGHT) — Sight Sciences
- [TARS](https://biopharmsignal.com/company/TARS) — Tarsus Pharmaceuticals